U.S. Markets closed

Millendo Therapeutics, Inc. to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference

ANN ARBOR, Mich.--(BUSINESS WIRE)--

Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.

Details on the Presentations:

Event: Cowen & Company 39th Annual Health Care Conference
Date/Time: Monday, March 11, 2019 at 1:30 p.m. ET
Location: Boston, MA

Event: Oppenheimer 29th Annual Healthcare Conference
Date/Time: Tuesday, March 19, 2019 at 3:55 p.m. ET
Location: New York, NY

Live webcasts of both presentations will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. Replays of the webcasts will be archived on Millendo’s website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome. For more information, please visit www.millendo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005147/en/